Your session is about to expire
← Back to Search
rF1V Vaccine with Adjuvant for Plague
Study Summary
This trial will compare the safety and effectiveness of two different vaccines for adults ages 18-55.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 18 and 55 years old.I have had a heart attack or have been diagnosed with heart disease.I do not have active tuberculosis or any other serious infection.I am not pregnant, breastfeeding, or planning to become pregnant.I haven't received certain vaccines, steroids, or other specific treatments recently.I am currently undergoing or will undergo chemotherapy, and was diagnosed with cancer other than skin cancer in the last 5 years.I have a history of HIV, HBV, or HCV, or tested positive for them.I am healthy or have stable pre-existing conditions.I have used reliable birth control for the last 28 days and will continue for 28 days after my last injection.You have an IUD (a birth control device placed in the uterus) with or without hormones.
- Group 1: Part 2 Group 1 & 3, OR Group 2 & 3
- Group 2: Part 1 Group 2:rF1V vaccine and CpG 1018® adjuvant bedside mix
- Group 3: Part 1 Group 1:rF1V vaccine and CpG 1018® adjuvant co-administered
- Group 4: Part 1 Group 3: rF1V vaccine and placebo
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many study participants are there in total?
"This clinical trial needs 200 individuals that fit the given inclusion criteria. There are many sites where patients can take part in this research, such as Optimal Research California and Optimal Research Texas."
Has the FDA cleared rF1V vaccine and CpG 1018® adjuvant for use?
"While there is some clinical evidence suggesting that the rF1V vaccine and CpG 1018® adjuvant are safe, Power rates this as a 2 because there is no data supporting efficacy."
Could I join the ranks of this research project?
"In order to participate in this trial, patients must be aged 18-55 and have plague. Additionally, the following criteria must be met: adults aged 18-55 years old, in good health or with a pre-existing medical condition that is under control, no major changes in medication within 3 months of Day 1, no recent surgical procedures or hospitalizations/emergency room visits related to the specific medical condition, willing and able to comply with the study schedule and procedures, willing and able to provide written informed consent, using contraception as specified below.This trial is looking for 200 participants who meet the above criteria."
Is this clinical trial prominent in the United States?
"Optimal Research is administering this clinical trial from 6 different locations: California, Texas, Florida, and 3 additional sites."
Do people outside of the target age range often try to get into these kind of studies?
"This particular trial is only open to patients aged 18-55, however there are other clinical trials that welcome patients outside of this age range. For example, there are 6 trials for those under 18 years old and 4 trials for patients over 65."
Is it possible to enroll in this research project at the present time?
"According to the most up-to-date information available on clinicaltrials.gov, this trial is still recruiting patients. The listing for this study was first posted on August 9th, 2022 and edited most recently on August 16th of the same year."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger